Physiomics PLC Issue of Options (8869J)
22 December 2015 - 11:08PM
UK Regulatory
TIDMPYC
RNS Number : 8869J
Physiomics PLC
22 December 2015
Physiomics plc
(the "Company" or "Physiomics")
Issue of Options
The Company confirms that it has agreed to issue share options
to each of its directors, as follows:
1. 64,523,106 share options over ordinary shares in the Company
("Share Options") have been granted to each of Mark Chadwick and
Christophe Chassagnole under the Enterprise Management Initiative
Scheme ("EMI"). The options are exercisable at a price of 0.035p
each (being the average mid-market closing price for the three days
prior to the date of issue).
2. A total of 25,809,242 share options over ordinary shares in
the Company ("Additional Share Options") have been granted to Paul
Harper under an Unapproved Share Option Scheme. The options are
exercisable at a price of 0.035p each.
The options vest after 3 months and can be exercised within 10
years of the date of grant.
If both the Share Options and Additional Shares Options were to
be exercised, they would represent 4.45% of the fully diluted,
issued share capital of the Company.
Following this issue, Mark Chadwick and Christophe Chassagnole
will each hold options over 137,936,532 ordinary shares in the
Company and Paul Harper will hold options over 55,174,612 share
options ordinary shares in the Company in accordance with the table
below.
Share Options
Award Granted Exercise Expiry
no. price date
p
Paul Harper 1 2,327,710 0.15 18-Dec-18
2 7,664,541 0.40 28-Feb-20
3 1,293,250 0.34 08-Nov-21
4 5,175,248 0.132 11-Feb-23
5 12,904,621 0.062 23-Mar-25
6 25,809,242 0.035 20-Dec-25
Christophe Chassagnole 1 7,499,453 0.383 06-Sep-17
2 5,624,590 0.15 18-Dec-18
3 11,856,584 0.40 28-Feb-20
4 3,233,125 0.34 08-Nov-21
5 12,938,121 0.132 11-Feb-23
6 32,261,553 0.062 23-Mar-25
7 64,523,106 0.035 20-Dec-25
Mark Chadwick 1 19,984,500 0.27 05-Dec-20
2 3,233,127 0.34 08-Nov-21
3 4,996,125 0.293 18-Dec-21
11-Feb
4 12,938,121 0.132 23
5 32,261,553 0.062 23-Mar-25
6 64,523,106 0.035 20-Dec-25
Enquiries:
Physiomics plc
Mark Chadwick
+44 (0)1865 784980
WH Ireland Limited
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTTBTTMBMTBRA
(END) Dow Jones Newswires
December 22, 2015 07:08 ET (12:08 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024